Background As the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) continues to rise, drug development has accelerated, with growing interest in therapeutic strategies that harness metabolic hormones. Metabolic hormone-based approaches, particularly those originally developed for obesity and diabetes, have shown potential to mitigate MASH. Notably, the glucagon-like peptide-1 receptor (GLP-1R) agonist sema...